The FDA and Hydrocodone

Hydrocodone-acetaminophen combinations are moved to Schedule II from Schedule III while single-agent extended release hydrodocone is approved without a tamper-resistant mechanism. Here, pain specialist Dr Steven King opines on both FDA decisions.
Source: Consultant Live - Category: Primary Care Source Type: news